Atypical mood stabilizers: a 'typical' role for atypical antipsychotics

被引:22
作者
Malhi, GS
Berk, M
Bourin, M
Ivanovski, B
Dodd, S
Lagopoulos, J
Mitchell, PB
机构
[1] Prince Wales Med Res Inst, Mayne Clin Res Imaging Ctr, Randwick, NSW 2031, Australia
[2] Prince Wales Hosp, Black Dog Inst, Mood Disorders Unit, Sydney, NSW, Australia
[3] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia
[4] Univ Melbourne, Dept Clin & Biomed Sci, Melbourne, Vic, Australia
[5] Barwon Hlth, Community & Mental Hlth, Geelong, Vic, Australia
[6] Orygen Res Ctr, Parkville, Vic, Australia
[7] Univ Nantes, Fac Med, Nantes, France
关键词
bipolar disorder; atypical antipsychotics; mood stabilizers; treatment;
D O I
10.1111/j.1600-0447.2005.00524.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To assess the potential role of atypical antipsychotics as mood stabilizers. Method: A MedLine, PsychLIT, PubMed, and EMBASE literature search of papers published up to December 2004 was conducted using the names of atypical antipsychotics and a number of key terms relevant to bipolar disorder. Additional articles were retrieved by scrutinizing the bibliographies of review papers and literature known to the authors. Data pertinent to the objective was reviewed according to the various phases of bipolar disorder. Results: The data is most substantive for the use of atypical antipsychotics in mania, to the extent that an argument for a class effect of significant efficacy can be made. This does not extend to bipolar depression, however, good data is now emerging for some agents and will need to be considered for each individual agent as it accumulates. As regards mixed states and rapid cycling the evidence is thus far sparse and too few maintenance studies have been conducted to make any firm assertions. However, with respect to long-term therapy the atypical antipsychotics do have clinically significant side-effects of which clinicians need to be aware. Conclusion: Based on the evidence thus far it is perhaps premature to describe the atypical antipsychotics as mood stabilizers. Individual agents may eventually be able to claim this label, however, much further research is needed especially with respect to maintenance and relapse prevention.
引用
收藏
页码:29 / 38
页数:10
相关论文
共 93 条
[1]   The evolving bipolar spectrum - Prototypes I, II, III, and IV [J].
Akiskal, HS ;
Pinto, O .
PSYCHIATRIC CLINICS OF NORTH AMERICA, 1999, 22 (03) :517-+
[2]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[3]   Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland [J].
Atkin, K ;
Kendall, F ;
Gould, D ;
Freeman, H ;
Lieberman, J ;
OSullivan, D .
BRITISH JOURNAL OF PSYCHIATRY, 1996, 169 (04) :483-488
[4]   Olanzapine versus placebo in acute mania - Treatment responses in subgroups [J].
Baldessarini, RJ ;
Hennen, J ;
Wilson, M ;
Calabrese, J ;
Chengappa, R ;
Keck, PE ;
McElroy, SL ;
Sachs, G ;
Vieta, E ;
Welge, JA ;
Yatham, LN ;
Zarate, CA ;
Baker, RW ;
Tohen, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) :370-376
[5]   Response to clozapine in acute mania is more rapid than that of chlorpromazine [J].
Barbini, B ;
Scherillo, P ;
Benedetti, F ;
Crespi, G ;
Colombo, C ;
Smeraldi, E .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 (02) :109-112
[6]   Olanzapine compared to lithium in mania: a double-blind randomized controlled trial [J].
Berk, M ;
Ichim, L ;
Brook, S .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (06) :339-343
[7]   'Bipolar missed states': the diagnosis and clinical salience of bipolar mixed states [J].
Berk, M ;
Dodd, S ;
Malhi, GS .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2005, 39 (04) :215-221
[8]  
BOURIN M, 2003, ANN M AM PSYCH ASS M
[9]  
BRECHER M, 2003, BIPOLAR DISORD S, V5, P35
[10]  
CALABRESE JR, 2004, AM PSYCH ASS 2004 AN